• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

ALDH2 Suppresses Multiple Myeloma Progression by Restraining the E2F Signaling Pathway

by
November 11, 2026
in Cancer, Health
Reading Time: 4 mins read
0
ALDH2 Suppresses Multiple Myeloma Progression by Restraining the E2F Signaling Pathway

ALDH2 Suppresses Multiple Myeloma Progression by Restraining the E2F Signaling Pathway

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Multiple myeloma, an incurable malignancy of plasma cells defined by repeated clinical relapse and the development of therapeutic resistance, poses an ongoing challenge that demands the discovery of microenvironment-related prognostic biomarkers and mechanistic drivers. In a newly published investigation, researchers evaluated the clinical significance, regulatory mechanisms, and biological functions of aldehyde dehydrogenase 2, known as ALDH2, in multiple myeloma progression. The authors identified ALDH2 as an independent favorable prognostic biomarker that exerts tumor-suppressive activity against the disease by suppressing the E2F signaling axis. Their findings demonstrate that elevated ALDH2 expression correlates with significantly prolonged survival outcomes and superior responses to therapy, while directly impeding the proliferative capacity of malignant cells.

To identify clinically meaningful molecular targets within the multiple myeloma microenvironment, the investigators initiated their workflow by analyzing single-cell RNA sequencing data cataloged under accession number GSE271107. This transcriptomic analysis focused on identifying differentially expressed genes within plasmacytoid dendritic cells, comparing cellular profiles derived from multiple myeloma patients directly against those from healthy donors. Following this initial identification, the researchers applied integrated bioinformatics strategies, combining the construction of protein-protein interaction networks with least absolute shrinkage and selection operator, or LASSO, penalized Cox regression modeling. Through this computational screening process, ALDH2 was successfully prioritized as a central prognostic hub gene originating from plasmacytoid dendritic cell-associated differential expression profiles.

Following the identification of ALDH2 as a primary candidate hub gene, the research team validated its prognostic utility across multiple independent patient cohorts, specifically datasets GSE4581, GSE24080, and GSE82307. Across these independent cohorts, high expression levels of ALDH2 consistently showed a statistically significant association with prolonged overall survival among multiple myeloma patients. Patients exhibiting elevated ALDH2 expression also demonstrated superior therapeutic responses compared to those with lower expression levels. To assess whether this association persisted when adjusting for other clinical variables, the investigators performed multivariate Cox regression modeling, which confirmed that ALDH2 expression operates as an independent favorable prognostic factor for patients diagnosed with multiple myeloma.

The investigation further explored how ALDH2 relates to immune infiltration dynamics and cellular abundance within the multiple myeloma tumor microenvironment. Through comprehensive immune infiltration evaluations and correlation analyses, the authors observed a distinct negative correlation between ALDH2 expression levels and the overall abundance of malignant plasma cells. This relationship suggests that higher levels of ALDH2 correspond to a reduced burden of malignant plasma cells in the evaluated tissue samples. By linking transcriptomic profiles to immune infiltration metrics, these analyses provided additional context regarding how microenvironment-associated metabolic regulation connects to disease status in multiple myeloma.

To delineate the downstream biological mechanisms associated with ALDH2 activity, the researchers conducted gene set enrichment analysis across patient transcriptomic profiles. The gene set enrichment analysis demonstrated that patient samples characterized by high ALDH2 expression were significantly negatively enriched in the E2F signaling pathway, pointing to an inhibitory effect on this critical cell cycle regulatory route. Correlational evaluations at the individual gene level further substantiated these pathway-level observations. Specifically, ALDH2 expression exhibited significant negative correlations with the key cell cycle regulators CCND2, CDK4, CDK6, and E2F1, while displaying a significant positive correlation with the retinoblastoma protein gene, RB1, indicating a coordinated suppression of cell cycle progression.

In addition to transcriptomic evaluations, the researchers evaluated the clinical utility of circulating ALDH2 as a minimally invasive biomarker through enzyme-linked immunosorbent assays performed on serum samples. The cohort evaluated in this clinical phase comprised 47 patients with multiple myeloma alongside 80 healthy control subjects. The laboratory assays demonstrated that serum ALDH2 concentrations were significantly reduced in multiple myeloma patients relative to the healthy controls. Furthermore, circulating ALDH2 concentrations were markedly lower in patients who demonstrated poor responses to therapy, achieving an area under the receiver operating characteristic curve of 0.89 for predicting therapeutic response. These serum measurements suggest that circulating ALDH2 levels hold promise for patient disease stratification and the prediction of treatment efficacy.

To experimentally verify the biological effects indicated by bioinformatics and clinical observations, the investigators performed in vitro gain-of-function and loss-of-function experiments using established myeloma cell lines, specifically U266 and LAMA-84. Functional assays measuring cellular proliferation and programmed cell death revealed that overexpression of ALDH2 directly suppressed multiple myeloma cell proliferation and significantly promoted cellular apoptosis. At the molecular level, forced ALDH2 overexpression resulted in the downregulation of proliferating cell nuclear antigen, or PCNA, an established marker of active cellular replication. Concurrently, ALDH2 overexpression led to the measurable upregulation of key cyclin-dependent kinase inhibitors, specifically CDKN1A and CDKN2A, reinforcing the role of ALDH2 in cell cycle arrest.

Synthesizing their transcriptomic, clinical, and experimental data, the authors concluded that ALDH2 serves as a functional tumor suppressor and an independent favorable prognostic biomarker in multiple myeloma. By restraining the E2F signaling pathway, ALDH2 curbs uncontrolled multiple myeloma cell proliferation and facilitates apoptotic clearance. Furthermore, because serum ALDH2 concentrations correlate strongly with therapeutic outcomes, circulating measurements present an accessible approach for disease stratification and therapeutic response prediction. The authors emphasized that these findings offer meaningful mechanistic insights into microenvironment-associated metabolic regulation during plasma cell malignancy while establishing ALDH2 as a viable candidate for future therapeutic targeting strategies.

Subject of Research: Prognostic and functional tumor-suppressive role of ALDH2 in multiple myeloma

Article Title: ALDH2 functions as an independent favorable prognostic biomarker and suppresses multiple myeloma progression through regulation of the E2F signaling pathway

Article References: Cai, L., Chen, D., Zhou, Y., Cong, Z., Jiang, Q., Zhu, L., Xu, X., & Shen, Q. (2026). ALDH2 functions as an independent favorable prognostic biomarker and suppresses multiple myeloma progression through regulation of the E2F signaling pathway. Discover Oncology. https://doi.org/10.1007/s12672-026-06202-7

Image Credits: AI Generated

DOI: 10.1007/s12672-026-06202-7

Keywords: Multiple Myeloma, ALDH2, E2F Signaling Pathway, Plasmacytoid Dendritic Cells, Single-Cell RNA Sequencing, LASSO-Cox Regression, Protein-Protein Interaction Network, Prognostic Biomarker, Overall Survival, Malignant Plasma Cells, Tumor Microenvironment, Cell Cycle Regulation, U266 Cell Line, LAMA-84 Cell Line, Serum ELISA, Therapeutic Response Prediction, Apoptosis, Cell Proliferation

News Source: Drew Townsend. (November 11, 2026). ALDH2 Suppresses Multiple Myeloma Progression by Restraining the E2F Signaling Pathway. Scienmag.

Tags: ALDH2Apoptosiscell cycle regulationCell proliferationE2F Signaling PathwayLAMA-84 Cell LineLASSO Cox regressionMalignant Plasma Cellsmultiple myelomaoverall survivalplasmacytoid dendritic cellsprognostic biomarkerprotein-protein interaction networkSerum ELISAsingle-cell RNA sequencingTherapeutic Response Predictiontumor microenvironmentU266 Cell Line
Share12Tweet7Share2ShareShareShare1

Related Posts

Periarticular Triamcinolone Injection Improves Early Quadriceps Recovery Following Total Knee Arthroplasty

Periarticular Triamcinolone Injection Improves Early Quadriceps Recovery Following Total Knee Arthroplasty

November 19, 2026
Computational Model Links Delayed Multisensory Shift in Autism to Reduced Plasticity

Computational Model Links Delayed Multisensory Shift in Autism to Reduced Plasticity

November 19, 2026

Participatory Systems Modelling Builds Stakeholder Consensus for Youth Mental Health in Bogotá

November 19, 2026

Hypoxic Ventilation During ECMO Could Promote Lung Growth in Pulmonary Hypoplasia

November 19, 2026

POPULAR NEWS

  • Study Finds Autism Diagnosed in Twenty-Eight Percent of Children With Neurofibromatosis Type 1

    Study Finds Autism Diagnosed in Twenty-Eight Percent of Children With Neurofibromatosis Type 1

    29 shares
    Share 12 Tweet 7
  • Esketamine with Pulsed Radiofrequency Alleviates Neuropathic Pain in Herpes Zoster Patients

    29 shares
    Share 12 Tweet 7
  • Fences Restrict Movement and Alter Space Use in Endangered Masai Giraffes

    29 shares
    Share 12 Tweet 7
  • Stem Cell Delivery Repairs Post-Stroke Endoplasmic Reticulum Dynamics in Rat Model

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Periarticular Triamcinolone Injection Improves Early Quadriceps Recovery Following Total Knee Arthroplasty

Computational Model Links Delayed Multisensory Shift in Autism to Reduced Plasticity

Chaotic Red Panda Optimization Improves Deep Learning for Date Palm Disease Detection

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.